Kane BiotechKNBIF Receivables Turnover is 2.00 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 848 Biotechnology companies, Kane Biotech ranks worse than 94.58% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kane Biotech's Revenue for the
three
months ended in Mar. 2026 was $0.03 Mil. Kane Biotech's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.02 Mil.
Hence, Kane Biotech's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.00.
Kane Biotech (OTCPK:KNBIF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Kane Biotech Receivables Turnover Related Terms
Kane Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Kane Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Kane Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Kane Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (KNBIF) has a Receivables Turnover of 2.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kane Biotech and its competitors. According to the industry distribution chart, Kane Biotech ranks #802 out of 848 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Kane Biotech's Receivables Turnover too high?
Kane Biotech's current Receivables Turnover is 2.00. The Biotechnology industry median Receivables Turnover is 5.29. Kane Biotech's value of 2.00 is 62.2% below this industry median. Based on the distribution chart, Kane Biotech ranks #802 out of 848 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Kane Biotech's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #802 out of 848 companies for Receivables Turnover. This places Kane Biotech in the lower half of its industry. The industry median Receivables Turnover is 5.29. Kane Biotech's value of 2.00 is 62.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kane Biotech's current Receivables Turnover of 2.00 is 62.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kane Biotech and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current Receivables Turnover is 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Receivables Turnover of 2.00. The current Receivables Turnover is 2.00 and 62.2% below the Biotechnology industry median of 5.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Receivables Turnover is 2.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 